You are here: Home » Markets ¬Ľ News
Cryptoverse: After Merge, ether heads for a $20-bn Shanghai splurge
Business Standard

Nifty Pharma index sees biggest jump in four months, shows data

The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year

Topics
Nifty Pharma | Pharma stocks | Cipla

Sundar Sethuraman  |  Thiruvananthapuram 



equity market, stocks, share market
Even after the latest surge, the Nifty Pharma index is down 10.4% on a YTD even as the Nifty has gained 2.7%

Pharma shares rallied on Tuesday as investors looked to prune exposure from pockets that have rallied and move money into the ones which have been laggards.

The index finished at 12,750, up 3.1 per cent — most since May 20 and third biggest single-day gain of the year. By comparison, the Nifty50 index finished with 1.1 per cent gain. Barring two, all components of the 20-share index rallied, with and surging the most at 5.5 per cent and 4.7 per cent, respectively.

The pharma sector is seen as a defensive play. It tends to outperform the market during periods of uncertainty and could underperform during bullish spells. This was seen over the past three months as the Nifty50 rallied as much as 18 per cent after bottoming out in June but the rallied only 8 per cent.

The have underperformed the market even on a year-to-date (YTD) basis. Even after the latest surge, the is down 10.4 per cent YTD even as the Nifty has gained 2.7 per cent.

Currently, while the market is hovering close to its record levels, concerns around inflation, global growth outlook and interest rate increases by the have created an uncertain environment for equities. This backdrop could benefit pharma stocks, say experts, given the valuation comfort.

chart

“A study of nearly 100 pharma, hospital, API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing) players, and path labs indicate that stocks in the healthcare segment are no longer expensive. Two third of the universe is trading below their past 13-year average price-to-earnings (P/E) and nearly a similar number of companies are trading below their historical EV/EBITDA (enterprise value to earnings before interest, tax, depreciation and amortization) multiples,” said DSP Mutual Fund in a recent note.

“Valuations are attractive and it is quite possible that this is an opportune time to scout for bottoms up opportunities in healthcare space with a time horizon of more than three years,” the note added.

On a P/E multiple basis, the Nifty Pharma index is available at close to historical valuations, while the Nifty50 is expensive, compared to historical averages.

The 12-month forward P/E for the Nifty Pharma index is currently at 25 times, same as its five-year average. Valuations have come off from a peak of 31x in January 2021. During the peak of Covid-19 selloff in March 2020, valuations for the sector had dropped to 16x.


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, September 20 2022. 18:26 IST

RECOMMENDED FOR YOU

.